• Turnaround time:
    10–21 calendar days (14 days on average)
  • Preferred specimen:
    3mL whole blood in a purple-top tube
  • Alternate specimens:
    DNA or saliva/assisted saliva
  • Sample requirements
  • Request a sample kit




Associated disorders

The MC1R gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant cutaneous malignant melanoma (MedGen UID: 416516).

Order single gene


Order this gene as a single gene test.

Order a test

Invitae tests that include this gene:

The MC1R gene encodes melanocortin 1 receptor, which is located on melanocytes and plays a role in normal pigmentation. The MC1R gene is also active in cells related to immune and inflammatory response.

MC1R heterozygotes
MedGen UID: 416516

Clinical condition
Common polymorphisms in the MC1R gene are associated with variation in skin, hair, and eye color and some variants are associated with UV induced genomic instability (Genetics Home Reference. MC1R. https://ghr.nlm.nih.gov/gene/MC1R. Accessed March 2016). MC1R currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant cutaneous malignant melanoma (PMID: 26488006, 19464594, 26337759, 18366057, 26938746, 18484624, 25790105, 21128237, 16280005, 26850723). Therefore, MC1R is considered a “preliminary-evidence” gene and is available on Invitae’s Melanoma Panel. Preliminary-evidence genes are selected from an extensive review of the literature and expert recommendations, but the association between the gene and the specific condition has not been completely established. This uncertainty may be resolved as new information becomes available, and therefore clinicians may continue to order these preliminary-evidence genes.

Gene information
The MC1R gene encodes the melanocortin 1 receptor. This receptor is primarily located on the surface of melanocytes. Melanocytes produce melanin and play an important role in normal pigmentation of skin, hair, and eyes. Melanin is also found in the retina (National Library of Medicine. Genetics Home Reference. MC1R. https://ghr.nlm.nih.gov/gene/MC1R. Accessed March 2016). Non-pigmentary functions have been described including regulation of inflammatory and oxidative responses, melanocyte proliferation, and UV induced DNA damage repair (PMID: 26850723).

The preliminary evidence associating MC1R variants with cutaneous melanoma suggests dominant inheritance. This means that an individual with such a variant has a 50% chance of passing the variant on to their offspring.

Because the evidence regarding MC1R and autosomal dominant cutaneous melanoma is limited and preliminary, there are currently no guidelines or recommendations to suggest alteration to medical management based solely on the presence of an MC1R variant. However, an individual’s cancer risk and medical management are not determined by genetic test results alone. Overall cancer risk assessment incorporates additional factors including personal medical history, family history as well as available genetic information that may result in a personalized plan for cancer prevention and surveillance.

Even though data regarding MC1R is limited, knowing if a pathogenic variant is present is advantageous. At-risk relatives can be identified, enabling pursuit of a diagnostic evaluation. Further, the available information regarding hereditary cancer susceptibility genes is constantly evolving and more clinically relevant data regarding MC1R are likely to become available in the near future. Awareness of this cancer predisposition encourages patients and their providers to inform at-risk family members, to consider implementing proposed screening protocols, and to be vigilant in maintaining close and regular contact with their local genetics clinic in anticipation of new information.

Review date: March 2016

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
MC1R NM_002386.3